This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

- 1. (Currently amended) A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time less than ten minutes after the onset of reperfusion, and continuing for a period of more than 30 minutes following the onset of reperfusion.
- 2. (Previously presented) A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following cardiac surgery.
- 3. (Previously presented) A method according to claim 1, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
- 4. (Currently amended) A method according to claim 1, wherein the administering of the compound begins at the onset of reperfusion, and continues for a period of more than 30 minutes following the onset of reperfusion.
- 5. (Previously presented) A method according to claim 1, wherein the administering of the compound is continued for a period of more than 70 minutes after the onset of reperfusion.
- 6. (Previously presented) A method according to claim 1, wherein the compound is of the formula

or a pharmaceutically acceptable salt thereof.

- 7. (Previously presented) A method according to claim 1, wherein the compound is administered as a pharmaceutically acceptable salt thereof.
- 8. (Previously presented) A method according to claim 1, wherein the compound administered is contained in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound.
- 9. (Currently amended) A method of providing cardioprotection, or protecting against reperfusion injury, or protecting against ischemic injury, in a patient in need thereof comprising administering to said patient a pharmaceutically effective amount of a compound having adenosine A1/A2 agonistic activity, beginning at a time 10 minutes or more before the onset of reperfusion, and continuing for a period of more than 30 minutes after the onset of reperfusion.
- 10. (Previously presented) A method according to claim 9, wherein the cardioprotection is provided prior to, during, or following cardiac surgery.

- 11. (Previously presented) A method according to claim 9, wherein the cardioprotection is provided prior to, during, or following ischemic attack.
- 12. (Previously presented) A method according to claim 9, wherein the administering of the compound is continued for a period of more than 70 minutes after the onset of reperfusion.
- 13. (Previously presented) A method according to claim 9, wherein the compound is of the formula

or a pharmaceutically acceptable salt thereof.

- 14. (Previously presented) A method according to claim 9, wherein the compound is administered as a pharmaceutically acceptable salt thereof.
- 15. (Previously presented) A method according to claim 9, wherein the compound administered is contained in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the compound.